Morton, and R. R. Weichselbaum (eds.), Cancer Medicine, pp. 1080 –
1119. Philadelphia: Lea & Fibiger, 1993.
2. Middlemas, D. S., Stewart, C. F., Kirstein, M. N., Poquette, C.,
Friedman, H. S., Houghton, P. J., and Brent, T. P. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft
models. Clin. Cancer Res., 6: 998 –1007, 2000.
3. Batchelor, T. Temozolomide for malignant brain tumors. Lancet,
355: 1115–1116, 2000.
4. Osoba, D., Brada, M., Yung, W. K., and Prados, M. Health-related
quality of life in patients treated with temozolomide versus procarbazine for
recurrent glioblastoma multiforme. J. Clin. Oncol., 18: 1481–1491, 2000.
5. Pluda, J. M. Tumor-associated angiogenesis: mechanisms, clinical
implications, and therapeutic strategies. Semin. Oncol., 24: 203–218,
1997.
6. Norrby, K. Angiogenesis: new aspects relating to its initiation and
control. APMIS, 105: 417– 437, 1997.
7. Fox, S. B., and Harris, A. L. Markers of tumor angiogenesis: clinical
applications in prognosis and anti-angiogenic therapy. Invest. New
Drugs, 15: 15–28, 1997.
8. Risau, W. What, if anything, is an angiogenic factor? Cancer Me-tastasis Rev., 15: 149 –151, 1996.
9. Singh, R. K., and Fidler, I. J. Regulation of tumor angiogenesis by
organ-specific cytokines. Curr. Top. Microbiol. Immunol., 213: 1–11,
1996.
10. Iruela-Arispe, M. L., and Dvorak, H. F. Angiogenesis: a dynamic
balance of stimulators and inhibitors. Thrombosis Haemostasis, 78:
672– 677, 1997.
11. Fukumura, D., Yuan, F., Monsky, W. L., Chen, Y., and Jain, R. K.
Effect of host microenvironment on the micro-circulation of human
colon adenocarcinoma. Am. J. Pathol., 151: 679 – 688, 1997.
12. Less, J. R., Posner, M. C., Skalak, T. C., Wolmark, N., and Jain,
R. K. Geometric resistance and microvascular network architecture of
human colorectal carcinoma. Microcirculation, 4: 25–33, 1997.
13. Jain, R. K. The Eugene M. Landis Award Lecture 1996. Delivery of
molecular and cellular medicine to solid tumors. Microcirculation, 4:
1–23, 1997.
14. Teicher, B. A. A systems approach to cancer therapy. Cancer
Metastasis Rev., 15: 247–272, 1996.
15. Teicher, B. A. (ed.). Antiangiogenic Agents in Cancer Therapy.
Totowa, NJ: Humana Press, 1999.
16. Ellis, L. M., Takahashi, Y., Liu, W., and Shaheen, R. M. Vascular
endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist, 5 (Suppl. 1): 11–15, 2000.
17. Xia, P., Aiello, L. P., Ishii, H., Jiang, Z. Y., Park, D. J., Robinson,
G. S., Takagi, H., Newsome, W. P., Jirousek, M. R., and King, G. L.
Characterization of vascular endothelial growth factor's effect on the
activation of protein kinase C, its isoforms, and endothelial cell growth.
J. Clin. Investig., 98: 2018 –2026, 1996.
18. Guo, D., Jia, Q., Song, H. Y., Warren, R. S., and Donner, D. B.
Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains.
Association with endothelial cell proliferation. J. Biol. Chem., 270:
6729 – 6733, 1995.
19. Sawano, A., Takahashi, T., Yamaguchi, S., and Shibuya, M. The
phosphorylated 1169-tyrosine containing region of flt-1 kinase
(VEGFR-1) is a major binding site for PLCg. Biochem. Biophys. Res.
Commun., 238: 487– 491, 1997.
20. McMahon, G. VEGF receptor signaling in tumor angiogenesis.
Oncologist, 5 (Suppl.1): 3–11, 2000.
21. Buchner, K. The role of protein kinase C in the regulation of cell
growth and in signalling to the cell nucleus. J. Cancer Res. Clin. Oncol.,
126: 1–11, 2000.
22. Martelli, A. M., Sang, N., Borgatti, P., Capitani, S., and Neri, L. M.
Multiple biological responses activated by nuclear protein kinase C. J.
Cell. Biochem., 74: 499 –521, 1999.
23. Mohammadi, M., Dikic, I., Sorokin, A., Burgess, W. H., Jaye, M.,
and Schlessinger, J. Identification of six novel autophosphorylation sites
